Improving the role of intraventricular antimicrobial agents in the management of meningitis

Current Opinion in Neurology

Volumn 22, Issue 3, 2009, Pages 277-282

  Ziai, Wendy C ^a,b   Lewin III, John J ^b  

^a Division of Neurosciences Critical Care   (United States)

^b DEPARTMENT OF PATHOLOGY   (United States)

Author keywords

Antimicrobial agents; Intraventricular; Meningitis; Shunt

Indexed keywords

AMIKACIN; AMINOGLYCOSIDE ANTIBIOTIC AGENT; ANTIBIOTIC AGENT; ANTIINFECTIVE AGENT; BETA LACTAM ANTIBIOTIC; CEFTRIAXONE; COLISTIN; GENTAMICIN; ISONIAZID; LEVOFLOXACIN; MORPHINE; PENICILLIN G; POLYMYXIN B; POLYMYXIN DERIVATIVE; POLYPEPTIDE ANTIBIOTIC AGENT; RIFAMPICIN; VANCOMYCIN;

BACTERIAL MENINGITIS; BLOOD BRAIN BARRIER; CEREBROSPINAL FLUID; DRUG BLOOD LEVEL; DRUG DIFFUSION; DRUG EFFICACY; DRUG HALF LIFE; DRUG MONITORING; DRUG PENETRATION; FUNGAL MENINGITIS; HUMAN; NONHUMAN; PRACTICE GUIDELINE; REVIEW; UNSPECIFIED SIDE EFFECT;

ANTI-INFECTIVE AGENTS; CEREBRAL VENTRICLES; CROSS INFECTION; HUMANS; INJECTIONS, INTRAVENTRICULAR; MENINGITIS, BACTERIAL; MICROBIAL SENSITIVITY TESTS; PRACTICE GUIDELINES AS TOPIC;

EID: 67049118106     PISSN: 13507540     EISSN: None     Source Type: Journal    
DOI: 10.1097/WCO.0b013e32832c1396     Document Type: Review

References (47)

1. Shah S, Ohlsson A, Shah V. Intraventricular antibiotics for bacterial meningitis in neonates. Cochrane Database Syst Rev 2004:CD004496.
2. McCracken GH, Mize SG, Threlkeld N. Intraventricular gentamicin therapy in Gram-negative bacillary meningitis of infancy. Report of the Second Neonatal Meningitis Cooperative Study Group. Lancet 1980; 1:787-791.
3. Mustafa MM, Mertsola J, Ramilo O, et al. Increased endotoxin and interleukin-1 beta concentrations in cerebrospinal fluid of infants with coliform meningitis and ventriculitis associated with intraventricular gentamicin therapy. J Infect Dis 1989; 160:891-895.
4. Hopkin DA. Intraventricular gentamicin [letter]. Lancet 1980; 1:799.
5. O'Neill E, Humphreys H, Phillips J, Smyth EG. Third-generation cephalosporin resistance among Gram-negative bacilli causing meningitis in neurosurgical patients: significant challenges in ensuring effective antibiotic therapy. J Antimicrob Chemother 2006; 57:356-359.
6. Lu CH, Chang WN, Chuang YC. Resistance to third-generation cephalos-porins in adult Gram-negative bacillary meningitis. Infection 1999; 27:208-211.
7. Nunez ML, Martinez-Toldos MC, Bru M, et al. Appearance of resistance to meropenem during the treatment of a patient with meningitis by Acinetobac-ter. Scand J Infect Dis 1998; 30:421-423.
8. Mancebo J, Domingo P, Blanch L, et al. Postneurosurgical and spontaneous Gram-negative bacillary meningitis in adults. Scand J Infect Dis 1986; 18: 533-538.
9. Falagas ME, Bliziotis IA, Tarn VH. Intraventricular or intrathecal use of poly-myxins in patients with Gram-negative meningitis: a systematic review of the vavailable evidence. Int J Antimicrob Agents 2007; 29:9-25. This is the largest recent systematic review of intraventricular/intrathecal use of an antibiotic (polymixins) for Gram-negative meningitis.
10. Lu CH, Chang WN, Chuang YC, Chang HW. Gram-negative bacillary meningitis in adult postneurosurgical patients. Surg Neurol 1999; 52:438-443.
11. Pikis A, Donkersloot JA, Akram S, et al. Decreased susceptibility to imipenem among penicillin-resistant Streptococcus pneumoniae. J Antimicrob Chemother 1997; 40:105-108.
12. Kearney BP, Aweeka FT. The penetration of antiinfectives into the central nervous system. Neurol Clin 1999; 17:883-900.
13. Lutsar I, McCracken GH Jr, Friedland IR. Antibiotic pharmacodynamics in cerebrospinal fluid. Clin Infect Dis 1998; 27:1117-1129.
14. Caricato A, Pennisi M, Mancino A, et al. Levels of vancomycin in the cerebral interstitial fluid after severe head injury. Intensive Care Med 2006; 32:325-328.
15. Bouw R, Ederoth P, Lundberg J, et al. Increased blood-brain barrier permeability of morphine in a patient with severe brain lesions as determined by microdialysis. Acta Anaesthesiol Scand 2001; 45:390-392.
16. Shen DD, Artu AA, Adkinson KK. Principles and applicability of CSF sampling for the assessment of CNS drug delivery and pharmacodynamics. Adv Drug Deliv Rev 2004; 56:1825-1857.
17. Pfausler B, Haring HP, Kampfl A, et al. Cerebrospinal fluid (CSF) pharma-cokinetics of intraventricular vancomycin in patients with staphylococcal ventriculitis associated with external CSF drainage. Clin Infect Dis 1997; 25:733-735.
18. Salmon JH. Ventriculitis complicating meningitis. Am J Dis Child 1972; 124:35-40.
19. Fan-Havard P, Nahata MC, Bartkowski MH, et al. Pharmacokinetics and cerebrospinal fluid (CSF) concentrations of vancomycin in pediatric patients undergoing CSF shunt placement. Chemotherapy 1990; 36:103-108.
20. Gump DW. Vancomycin for treatment of bacterial meningitis. Rev Infect Dis 1981;3:S289-S292.
21. Yogev R, Davis AT. Neurosurgical shunt infections. A review. Childs Brain 1980; 6:74-81.
22. Furey W, Ciric I, Parker RH. Monitoring of intrathecal polymyxin B dosage during treatment of pseudomonas meningitis. IMJ III Med J 1971; 139:506-510.
23. Polsky B, Depman MR, Gold J W, et al. Intraventricular therapy of cryptococcal meningitis via a subcutaneous reservoir. Am J Med 1986; 81:24-28.
24. Vincken W, Meysman M, Verbeelen D, et al. Intraventricular rifampicin in severe tuberculous meningo-encephalitis. Eur Respir J 1992; 5:891-893.
25. Chen Y, Chang F, Wang Z. Treatment of the secondary hydrocephalus of tuberculous meningitis by lateral ventricular drainage and drug injection. Zhonghua Jie He He Hu Xi Za Zhi 1996; 19:297-299.
26. Upton A, Woodhouse A, Vaughan R, et al. Evolution of central nervous system multidrug-resistant Mycobacterium tuberculosis and late relapse of cryptic prosthetic hip joint tuberculosis: complications during treatment of disseminated isoniazid-resistant tuberculosis in an immunocompromised host. J Clin Microbiol 2009; 47:507-510.
27. Williamson JC, Glazier SS, Peacock JE Jr. Successful treatment of ventricu-lostomy-related meningitis caused by vancomycin-resistant Enterococcus with intravenous and intraventricular quinupristin/ dalfopristin. Clin Neurol Neurosurg 2002; 104:54-56.
28. Shehab ZM, Britton H, Dunn JH. Imidazole therapy of coccidioidal meningitis in children. Pediatr Infect Dis J 1988; 7:40-44.
29. Peloquin CA. Antituberculosis drugs: pharmacokinetics. In: Heifets LB, editor. Drug susceptibility in the chemotherapy of mycobacterial infections. Boca Raton, FL: CRC Press; 1991. pp. 13-57.
30. Chicano-Piá PV, Cercòs-Lleti AC, Romá-Sanchez E. Pharmacokinetic model for tobramycin in Acinetobacter meningitis. Ann Pharmacother 2002; 36:83-86.
31. Kaiser AB, McGee ZA. Aminoglycoside therapy of Gram-negative bacillary meningitis. N Engl J Med 1975; 293:1215-1220.
32. Varelas PN, Rehman M, Pierce W, et al. Vancomycin-resistant enterococcal meningitis treated with intrathecal streptomycin. Clin Neurol Neurosurg 2008; 110:376-380. This article contains a literature review of patients treated with intrathecal antibiotics for enterococcal meningitis.
33. Sung JP, Campbell GD, Grendahl JG. Miconazole therapy for fungal meningitis. Arch Neurol 1978; 35:443-447.
34. Fukui S, Tabata H, Hayashi H, Matsushima Y. Successful treatment of Candida meningitis with miconazole. No To Shinkei 1990; 42:863-866.
35. Guardado R, Asensi V, Torres JM, et al. Postsurgical enterococcal meningitis: clinical and epidemiological study of 20 cases. Scand J Infect Dis 2006; 38:584-588.
36. Haase KK, Lapointe M, Haines SJ. Aseptic meningitis after intraventricular administration of gentamicin. Pharmacotherapy 2001; 21:103-107.
37. Richards SJ, Lambert CM, Scott AC. Recurrent Listeria monocytogenes meningitis treated with intraventricular vancomycin. J Antimicrob Chemother 1992; 29:351-353.
38. Morrison VA, Weinshel EL, Luikart SD. Corynebacterium JK: a new pathogen in ventriculostomy infections. J Neurooncol 1991; 11:65-69.
39. Preston SL, Briceland LL. Intrathecal administration of amikacin for treatment of meningitis secondary to cephalosporin-resistant Escherichia coli. Ann Pharmacother 1993; 27:870-873.
40. Kaplan MH, Rosen PP, Armstrong D. Cryptococcosis in a cancer hospital: clinical and pathological correlates in forty-six patients. Cancer 1977; 39:2265-2274.
41. Young RF, Gade G, Grinnell V. Surgical treatment for fungal infections in the central nervous system. J Neurosurg 1985; 63:371-381.
42. Berning SE, Cherry TA, Iseman MD. Novel treatment of meningitis caused by multidrug-resistant Mycobacterium tuberculosis with intrathecal levofloxacin and amikacin: case report. Clin Infect Dis 2001; 32:643-646.
43. Takahashi M, Yamada R, Tabei Y, et al. Navigation-guided Ommaya reservoir placement: implications for the treatment of leptomeningeal metastases. Minim Invasive Neurosurg 2007; 50:340-345.
44. Nau R, Sörgel F, Prange HW. Pharmacokinetic optimisation of the treatment of bacterial central nervous system infections. Clin Pharmacokinet 1998; 35:223-246.
45. Schwabe M, Juttner E, Blaich A, et al. Cure of ventriculitis and central nervous system shunt infection by Staphylococcus epidermidis with vancomycin by intraventricular injection in a liver transplant recipient. Transpl Infect Dis 2007; 9:46-50.
46. Reesor C, Chow AW, Kureishi A, Jewesson PJ. Kinetics of intraventricular vancomycin in infections of cerebrospinal fluid shunts. J Infect Dis 1988; 158:1142-1143.
47. Brown EM, Edwards RJ, Pople IK. Conservative management of patients with cerebrospinal fluid shunt infections. Neurosurgery 2008; 62 (Suppl 2):661-669. This is an observational study of conservative management of patients with CSF shunt infections with combination intraventricular and systemic antibiotics.